![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EMA Evaluates the Use of Kineret in Adult COVID-19 Patients
EMA Evaluates the Use of Kineret in Adult COVID-19 Patients
The European Medicines Agency (EMA) has begun reviewing Sobi’s Kineret (anakinra) for treating COVID-19 in adult pneumonia patients at risk of severe respiratory failure.
Kineret, an immunosuppressant drug first authorized in the EU in 2002, is meant to stop coronavirus-related inflammation and tissue damage by halting the activity of the interleukin 1 proteins.
The EMA’s human medicines committee is assessing data from two clinical trials and is expected to reach a decision by October, unless more information is required.
Upcoming Events
-
18Jul
-
21Oct